Cargando…

DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues

Identifying the primary site of metastatic cancer is critical to guiding the subsequent treatment. Approximately 3–9% of metastatic patients are diagnosed with cancer of unknown primary sites (CUP) even after a comprehensive diagnostic workup. However, a widely accepted molecular test is still not a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shirong, He, Shutao, Zhu, Xin, Wang, Yunfei, Xie, Qionghuan, Song, Xianrang, Xu, Chunwei, Wang, Wenxian, Xing, Ligang, Xia, Chengqing, Wang, Qian, Li, Wenfeng, Zhang, Xiaochen, Yu, Jinming, Ma, Shenglin, Shi, Jiantao, Gu, Hongcang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502058/
https://www.ncbi.nlm.nih.gov/pubmed/37709764
http://dx.doi.org/10.1038/s41467-023-41015-0
Descripción
Sumario:Identifying the primary site of metastatic cancer is critical to guiding the subsequent treatment. Approximately 3–9% of metastatic patients are diagnosed with cancer of unknown primary sites (CUP) even after a comprehensive diagnostic workup. However, a widely accepted molecular test is still not available. Here, we report a method that applies formalin-fixed, paraffin-embedded tissues to construct reduced representation bisulfite sequencing libraries (FFPE-RRBS). We then generate and systematically evaluate 28 molecular classifiers, built on four DNA methylation scoring methods and seven machine learning approaches, using the RRBS library dataset of 498 fresh-frozen tumor tissues from primary cancer patients. Among these classifiers, the beta value-based linear support vector (BELIVE) performs the best, achieving overall accuracies of 81-93% for identifying the primary sites in 215 metastatic patients using top-k predictions (k = 1, 2, 3). Coincidentally, BELIVE also successfully predicts the tissue of origin in 81-93% of CUP patients (n = 68).